You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT JAMA
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 274 No. 12, September 27, 1995 TABLE OF CONTENTS
  JAMA
  •  Online Features
  Grand Rounds at the Clinical Center of the National Institutes of Health
 This Article
 •References
 •Full text PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Similar articles in JAMA
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Clozapine Treatment of Schizophrenia

David Pickar, MD; John K. Hsiao, MD

JAMA. 1995;274(12):981-983.

Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

SELECTED CASE

A 27-year-old woman was admitted to the National Institutes of Health Clinical Center, Bethesda, Md, for inpatient research protocol for schizophrenia. She first experienced behavioral disturbances at 13 years of age when she became withdrawn and isolated from friends and family. She reported auditory hallucinations for the first time at 16 years and developed delusions of control and persecution over ensuing months. Suicidal ruminations culminated in a serious suicide attempt and her first hospitalization at the age of 17 years. Although standard antipsychotic drugs reduced her delusions, the patient remained socially isolated and had symptom exacerbation when under stress. She discontinued antipsychotic drug treatment because of adverse effects on several occasions; in each case, she became acutely psychotic. Prior to her admission to the National Institute of Mental Health, she was hospitalized 15 times, including several hospitalizations mandated by the court because of risk to herself and to . . . [Full Text PDF of this Article]


Author Affiliations

From the Experimental Therapeutics Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, Md.


Footnotes

Reprint requests to Experimental Therapeutics Branch, National Institute of Mental Health, National Institutes of Health, Bldg 10, Room 4N-212, Bethesda, MD 20892 (Dr Pickar).

Grand Rounds at the Clinical Center of the National Institutes of Health section editors: John I. Gallin, MD, the Clinical Center of the National Institutes of Health, Bethesda, Md; David S. Cooper, MD, Contributing Editor, JAMA.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 1995 American Medical Association. All Rights Reserved.